ClinicalTrials.gg
TerminatedNCT03880474Updated Apr 26, 2021Results posted

Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults

A Phase 2 interventional study of MVA-NP+M1 and Saline in Influenza, sponsored by Barinthus Biotherapeutics. Terminated at 9 sites in Australia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-26.

Sponsored by Barinthus Biotherapeutics · Phase 2, Interventional, and Prevention

How we know

Why this study was terminated
The trial is being stopped for futility. Season 2 cancelled.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
2,364
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 99 studies in Influenza, Human with a site in Australia — 8 open to participants now, 12 under way, 3 of them phase 3. Influenza, Human · Australia.

Enrollment
13th of 87
2,364 · median 360
Started
2019
with 3 others
Phase 2
27 of 99
1 open now
Registered
65th of 99
by date

Among the 99 studies in Influenza, Human with a site in Australia, this one is the 13th largest by enrollment of the 87 interventional ones that give a count, is one of 4 that started in 2019, is one of 27 in phase 2, and was the 65th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

8 of the 99 studies in Influenza, Human with a site in Australia are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Influenza, Human with a site in Australia, or all of them as a file.
02

Study summary

A Phase 2b Study to Determine the Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults aged 18 years and over. To assess the effect of MVA-NP+M1 on the reduction of laboratory confirmed influenza when given as an adjunct to licensed quadrivalent influenza vaccine (QIV) in adults

Read the detailed description

This is a Phase 2b, multicentre, randomised, single-blind study in up to 6000 adults to compare the efficacy, safety and immunogenicity of MVA-NP+M1 when given as an adjunct to a standard, licensed adult dose of QIV. The study will be conducted on an outpatient basis and will run over two consecutive influenza seasons. It is aimed to recruit 2200 participants in Season 1 and 2800-3800 participants in Season 2.

03

Conditions studied

  • Influenza

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female adults aged 18 years and over
  • Receipt of a standard-dose licensed influenza QIV vaccine on the day of, or within 28 days prior to, randomisation
  • A female participant is eligible for this study if she is not pregnant or breast feeding and one of the following:

    1. Of non- (i.e. women who have had a hysterectomy or tubal ligation or are , as defined by no menses in greater than or equal to 1 year)
    2. Of childbearing potential but agrees to practice effective 8 weeks post-vaccination and has a negative urine pregnancy test pre-vaccination. Acceptable methods of contraception include one or more of the following:

    i. Male partner who is sterile prior to the female participant's entry into the study and is the sole sexual partner for the female participant ii. Implants of levonorgestrel iii. Injectable progestogen iv. An intrauterine device with a documented failure rate of \<1% v. Oral contraceptives vi. Double barrier methods including diaphragm or condom vii. Abstinence as long as it is line with the usual and preferred lifestyle of the participant

  • Participant is willing and has capacity to provide written for participation in the study (in the Investigator's opinion)
  • Able and willing (in the Investigator's opinion) to comply with all study requirements
  • Willing to allow the Investigators to discuss the participant's medical history with their healthcare provider
  • Present and able to visit the clinic in the event of an ILI episode during the influenza season

Exclusion criteria

Exclusion Criteria:

  • Any other significant disease, disorder or finding (including blood test results), which, in the opinion of the Investigator, would either put the participant at risk because of participation in the study, or may influence the result of the study
  • Receipt of any product within 6 months prior to study, or prior participation in a clinical study of any Influenza vaccine and agreement not to participate in another clinical study for the duration of study follow-up
  • Prior receipt of an investigational vaccine likely to impact on interpretation of the study data
  • Active infection with , or (from patient history or medical records)
  • History of severe allergic reactions (e.g. anaphylaxis)
  • History of auto-immune disease e.g. Guillain-Barré syndrome
  • Not willing to comply with study procedures
  • or taking immunosuppressive medications
  • Use of warfarin or other blood thinning medications (aspirin is acceptable)
  • Tattoos or birthmarks at the vaccination site
  • Participant bruises easily, has haematoma or keloid scarring
  • Receipt of a licenced inactivated vaccine (e.g. pneumococcal vaccine) within 2 weeks prior to vaccination
  • Receipt of an off licensed (e.g. herpes zoster vaccine) within 4 weeks prior to vaccination
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,364 participants (actual)

Study arms

  • Experimental
    MVA-NP+M1

    Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10\^8 pfu.)

    Biological: MVA-NP+M1

  • Placebo comparator
    Saline Placebo

    Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%)

    Drug: Saline

Interventions

06

What researchers measure

Primary outcomes

  1. Number and Percentage of Participants With Laboratory Confirmed Influenza Using Reverse Transcription Polymerase Chain Reaction (RT-PCR).

    The measure used reverse transcription polymerase chain reaction (RT-PCR) on deep nasal/mid-turbinate swab samples to record confirmed cases of influenza. If influenza symptoms are experienced at any time during the Follow Up period, after the vaccination, participants will attend the clinic on two occasions, the first as soon as possible and at least within 72 hours of the onset of symptoms for deep nasal swabs to be taken. Both swabs must be taken within 96 hours of symptom onset. The incidence rate of laboratory confirmed influenza using RT-PCR will be estimated for each vaccine group. The 95% CI for the incidence rate will be estimated by mid-p exact method. The difference in incidence rate between vaccine groups will be compared by Fisher's exact method.

    Time frame: 210 days (during the influenza season, starting on 01 May 2019 and ending on or before 15 October 2019) in line with official Australian influenza season.

Secondary outcomes

  1. Number and Percentage of Participants With Influenza-like Illness (ILI) as Derived From Daily ILI eDiary

    ILI is defined as feeling feverish or having a fever (feeling feverish or having a fever (≥37.8Celsius)) and at least one of the following symptoms: cough, sore throat. The incidence rate of ILI by the participant completing of eDiaries will be estimated for each vaccine group. The 95% CI for the incidence will be estimated by mid-p exact method. The difference in incidence between groups will be compared by Fisher's exact method.

    Time frame: 210 days (during the influenza season, starting on 01 May 2019 and ending on or before 15 October 2019)

  2. Number and Percentage of Participants With Solicited Local and Systemic Reactogenicity Signs and Symptoms for 7 Days Following Vaccination (and Occurrence of Serious Adverse Events SAEs)

    The solicited adverse events are commonly observed soon after receipt of vaccines and relate to local and systemic signs and symptoms. The solicited local injection site reactions (ISR) include pain, induration, warmth, and erythema (redness). The solicited systemic reactions include feverishness, chills, myalgia, fatigue, headache, nausea, arthralgia, and malaise. Participants completed eDiaries post vaccination to record ISR and systemic reactogenicity over the first 7 days post-vaccination (and the ongoing (S)AEs throughout the study). The participant reporting of all ISR categories and solicited systemic reactions was compared between the MVA-NP+M1 treated group and the Placebo treated group. Diary reported ISRs and solicited systemic reactions were summarized, by vaccination group, using descriptive statistics.

    Time frame: 7 days to a total of 210 days for SAEs (over the duration of the influenza season, between 01 May and 15 October)

  3. Number of Participants With Immunogenic Response (Immunogenicity of MVA-NP+M1 in Adjunction With Licensed QIV as Assessed Via Titres of Influenza-specific Neutralizing Antibodies)

    The numbers of Immunogenic Participants (participants with positive immune response as assessed at Day 28 and week 26 in relation to the baseline day 0 Immunogenicity) were summarized and listed. The immunogenicity here was assessed as the geometric mean titers of influenza-specific neutralizing antibodies at different timepoints in relation to the baseline, against the antigens included in the licensed QIV(Influenza A/H3N2 (HI), Influenza A/H3N2 (MN), Influenza A/H3N2 (H1N1pdm), Influenza B/Victoria, and Influenza B/Yamagata). The neutralizing antibody assays included microneutralisation and hemagglutination inhibition titers using standard methodologies for the four strains that were in the licensed vaccine. The immunogenicity analyses were conducted only on the Immunology Analysis Set of Participants.

    Time frame: Day 28 and Week 26

  4. Duration of Influenza-like Illness (ILI) as Derived From Daily ILI eDiary

    The duration of ILI is defined as the duration (days) from the first day ILI criteria met (as defined at the Secondary Outcome Measure 2) until the first day afterwards ILI criteria not met (event, ILI recovery). ILI positive participants with ILI criteria met throughout the entire influenza season were censored at the last day recorded with the ILI dairy. Survival analysis was used for the analysis of duration of ILI. The survival function for the duration of ILI was estimated by the Kaplan-Meier method.

    Time frame: 210 days (during the influenza season, starting on 01 May 2019 and ending on or before 15 October 2019)

  5. Severity of Influenza-like Illness (ILI) Derived From Daily ILI eDiary as Time Weighted AUC

    The severity of ILI was assessed by each participant completing of electronic Diaries for symptom severity daily for the following symptoms: Feeling hot, Temperature, Cough, Sore throat, Blocked nose, Chest pain, Muscle aches, Shortness of breath with their severities (scores) recorded as: Not Present (0), Mild (1), Moderate (2), Severe (3). For each symptom, the severity score was used to calculate the area under the curve (AUC), along with the calendar day, for the entire influenza season using trapezoidal rule. Participants could be followed for varying days in the influenza season, therefore the AUC will be time weighted to 168 days: Time weighted AUC=((raw AUC \[time in days\])/(number of days used for analysis)) \* 168

    Time frame: 210 days (during the influenza season, starting on 01 May 2019 and ending on or before 15 October 2019)

  6. Number of Participants With Immunogenic Response to MVA-NP+M1 (as Assessed Via the Frequency of Influenza-specific T-cells)

    The numbers of immunogenic Participants (with positive immune response as assessed at Day 28 and week 26 in relation to the baseline day 0 Immunogenicity) were listed. The immunogenicity here was determined via the frequency of influenza-specific T-cells measured by IFN-γ/granzyme B ELISpot assay (enzyme linked immunospot) where the adjusted Spot Forming Units (SFU) per million PBMCs (peripheral blood mononuclear cells) after background subtraction (dimethyl sulfoxide, DMSO) were counted. The immunogenicity analyses were conducted only in the Immunology Analysis Set of Participants.

    Time frame: Day 28 and Week 26

07

Results

Posted Apr 26, 2021

Participant flow

The single-blind study was conducted at 9 sites across Australia, over one Influenza season.

Participant flow — Overall Study
MilestoneMVA-NP+M1 Group (Main Cohort + Immunogenicity Cohort)Saline Placebo Group (Main Cohort+ Immunogenicity Cohort)
Started10771075
Completed10541055
Not completed2320

Outcome measures

PrimaryNumber and Percentage of Participants With Laboratory Confirmed Influenza Using Reverse Transcription Polymerase Chain Reaction (RT-PCR).

The measure used reverse transcription polymerase chain reaction (RT-PCR) on deep nasal/mid-turbinate swab samples to record confirmed cases of influenza. If influenza symptoms are experienced at any time during the Follow Up period, after the vaccination, participants will attend the clinic on two occasions, the first as soon as possible and at least within 72 hours of the onset of symptoms for deep nasal swabs to be taken. Both swabs must be taken within 96 hours of symptom onset. The incidence rate of laboratory confirmed influenza using RT-PCR will be estimated for each vaccine group. The 95% CI for the incidence rate will be estimated by mid-p exact method. The difference in incidence rate between vaccine groups will be compared by Fisher's exact method.

Time frame:
210 days (during the influenza season, starting on 01 May 2019 and ending on or before 15 October 2019) in line with official Australian influenza season.
Reported as:
Count of participants · Participants
Number and Percentage of Participants With Laboratory Confirmed Influenza Using Reverse Transcription Polymerase Chain Reaction (RT-PCR).
ParticipantsMVA-NP+M1 GroupSaline Placebo Group
Participants with laboratory confirmed influenza using RT-PCR3523
Participants without laboratory confirmed influenza using RT-PCR10421052
Statistical analysis
  • MVA-NP+M1 Group vs Saline Placebo Group · Log Binominal Model · p = 0.1146 · Relative risk: 1.52 · 95% CI 0.90 to 2.55
  • MVA-NP+M1 Group vs Saline Placebo Group · Poisson Model with Robust Variance · p = 0.1146 · Relative risk: 1.52 · 95% CI 0.90 to 2.55
SecondaryNumber and Percentage of Participants With Influenza-like Illness (ILI) as Derived From Daily ILI eDiary

ILI is defined as feeling feverish or having a fever (feeling feverish or having a fever (≥37.8Celsius)) and at least one of the following symptoms: cough, sore throat. The incidence rate of ILI by the participant completing of eDiaries will be estimated for each vaccine group. The 95% CI for the incidence will be estimated by mid-p exact method. The difference in incidence between groups will be compared by Fisher's exact method.

Time frame:
210 days (during the influenza season, starting on 01 May 2019 and ending on or before 15 October 2019)
Reported as:
Count of participants · Participants
Number and Percentage of Participants With Influenza-like Illness (ILI) as Derived From Daily ILI eDiary
ParticipantsMVA-NP+M1 GroupSaline Placebo Group
Positive ILI Cases273273
Negative ILI Cases804802
Statistical analysis
  • MVA-NP+M1 Group vs Saline Placebo Group · Log Binomial Model · p = 1.0000 · Relative risk: 1 · 95% CI 0.86 to 1.15
  • MVA-NP+M1 Group vs Saline Placebo Group · Poisson Model with Robust Variance · p = 0.9799 · Relative risk: 1 · 95% CI 0.86 to 1.15
SecondaryNumber and Percentage of Participants With Solicited Local and Systemic Reactogenicity Signs and Symptoms for 7 Days Following Vaccination (and Occurrence of Serious Adverse Events SAEs)

The solicited adverse events are commonly observed soon after receipt of vaccines and relate to local and systemic signs and symptoms. The solicited local injection site reactions (ISR) include pain, induration, warmth, and erythema (redness). The solicited systemic reactions include feverishness, chills, myalgia, fatigue, headache, nausea, arthralgia, and malaise. Participants completed eDiaries post vaccination to record ISR and systemic reactogenicity over the first 7 days post-vaccination (and the ongoing (S)AEs throughout the study). The participant reporting of all ISR categories and solicited systemic reactions was compared between the MVA-NP+M1 treated group and the Placebo treated group. Diary reported ISRs and solicited systemic reactions were summarized, by vaccination group, using descriptive statistics.

Time frame:
7 days to a total of 210 days for SAEs (over the duration of the influenza season, between 01 May and 15 October)
Reported as:
Count of participants · Participants
Number and Percentage of Participants With Solicited Local and Systemic Reactogenicity Signs and Symptoms for 7 Days Following Vaccination (and Occurrence of Serious Adverse Events SAEs)
ParticipantsMVA-NP+M1 GroupSaline Placebo Group
Participants with Solicited Local Injection Site Reaction (IRS) - Pain29219
Participants with Solicited Local Injection Site Reaction (IRS) - Induration1134
Participants with Solicited Local Injection Site Reaction (IRS) - Warmth20518
Participants with Solicited Local Injection Site Reaction (IRS) - Erythema19815
Participants with Severe, Solicited Local Injection Site Reaction121
Participants with Solicited Systemic Reactions - Chills6118
Participants with Solicited Systemic Reactions - Myalgia25685
Participants with Solicited Systemic Reactions - Fatigue248117
Participants with Solicited Systemic Reactions - Headache238106
Participants with Solicited Systemic Reactions - Nausea8831
Participants with Solicited Systemic Reactions - Arthralgia15657
Participants with Solicited Systemic Reactions - Malaise273139
Participants with Solicited Systemic Reactions - Feverishness21493
Participants with Severe, Solicited Systemic Reaction4514
SecondaryNumber of Participants With Immunogenic Response (Immunogenicity of MVA-NP+M1 in Adjunction With Licensed QIV as Assessed Via Titres of Influenza-specific Neutralizing Antibodies)

The numbers of Immunogenic Participants (participants with positive immune response as assessed at Day 28 and week 26 in relation to the baseline day 0 Immunogenicity) were summarized and listed. The immunogenicity here was assessed as the geometric mean titers of influenza-specific neutralizing antibodies at different timepoints in relation to the baseline, against the antigens included in the licensed QIV(Influenza A/H3N2 (HI), Influenza A/H3N2 (MN), Influenza A/H3N2 (H1N1pdm), Influenza B/Victoria, and Influenza B/Yamagata). The neutralizing antibody assays included microneutralisation and hemagglutination inhibition titers using standard methodologies for the four strains that were in the licensed vaccine. The immunogenicity analyses were conducted only on the Immunology Analysis Set of Participants.

Time frame:
Day 28 and Week 26
Reported as:
Count of participants · Participants
Number of Participants With Immunogenic Response (Immunogenicity of MVA-NP+M1 in Adjunction With Licensed QIV as Assessed Via Titres of Influenza-specific Neutralizing Antibodies)
ParticipantsMVA-NP+M1 GroupSaline Placebo Group
Participants with Influenza Antibody Titer: ANCOVA Analysis Immunology, at Day 282324
Participants with Influenza Antibody Titer: ANCOVA Analysis Immunology, at Week 262325
Statistical analysis
  • MVA-NP+M1 Group vs Saline Placebo Group · ANCOVA · p = 0.3284 · Least squares mean difference: -287.1 · 95% CI -872.75 to 298.59
  • MVA-NP+M1 Group vs Saline Placebo Group · ANCOVA · p = 0.8468 · Least squares mean difference: -13.39 · 95% CI -152.26 to 125.47
  • MVA-NP+M1 Group vs Saline Placebo Group · ANCOVA · p = 0.5087 · Least squares mean difference: -465.7 · 95% CI -1875.21 to 943.75
  • MVA-NP+M1 Group vs Saline Placebo Group · ANCOVA · p = 0.7509 · Least squares mean difference: -83.68 · 95% CI -611.67 to 444.32
  • MVA-NP+M1 Group vs Saline Placebo Group · ANOVA · p = 0.3398 · Least squares mean difference: -81.17 · 95% CI -250.72 to 88.39
  • MVA-NP+M1 Group vs Saline Placebo Group · ANCOVA · p = 0.4154 · Least squares mean difference: 26.15 · 95% CI -37.95 to 90.26
  • MVA-NP+M1 Group vs Saline Placebo Group · ANCOVA · p = 0.7193 · Least squares mean difference: 22.84 · 95% CI -104.50 to 150.18
  • MVA-NP+M1 Group vs Saline Placebo Group · ANCOVA · p = 0.1496 · Least squares mean difference: 52.38 · 95% CI -19.59 to 124.35
  • MVA-NP+M1 Group vs Saline Placebo Group · ANCOVA · p = 0.9044 · Least squares mean difference: -16.76 · 95% CI -296.57 to 263.06
  • MVA-NP+M1 Group vs Saline Placebo Group · ANCOVA · p = 0.4198 · Least squares mean difference: 38.64 · 95% CI -56.97 to 134.24
SecondaryDuration of Influenza-like Illness (ILI) as Derived From Daily ILI eDiary

The duration of ILI is defined as the duration (days) from the first day ILI criteria met (as defined at the Secondary Outcome Measure 2) until the first day afterwards ILI criteria not met (event, ILI recovery). ILI positive participants with ILI criteria met throughout the entire influenza season were censored at the last day recorded with the ILI dairy. Survival analysis was used for the analysis of duration of ILI. The survival function for the duration of ILI was estimated by the Kaplan-Meier method.

Time frame:
210 days (during the influenza season, starting on 01 May 2019 and ending on or before 15 October 2019)
Reported as:
Median · days
Duration of Influenza-like Illness (ILI) as Derived From Daily ILI eDiary
daysMVA-NP+M1 GroupSaline Placebo Group
Duration of Influenza-like Illness (ILI) as Derived From Daily ILI eDiary3 (3 to 4)3 (3 to 4)
Statistical analysis
  • MVA-NP+M1 Group vs Saline Placebo Group · Regression, Cox · p = 0.4159 · Hazard ratio (hr): 1.08 · 95% CI 0.90 to 1.28
SecondarySeverity of Influenza-like Illness (ILI) Derived From Daily ILI eDiary as Time Weighted AUC

The severity of ILI was assessed by each participant completing of electronic Diaries for symptom severity daily for the following symptoms: Feeling hot, Temperature, Cough, Sore throat, Blocked nose, Chest pain, Muscle aches, Shortness of breath with their severities (scores) recorded as: Not Present (0), Mild (1), Moderate (2), Severe (3). For each symptom, the severity score was used to calculate the area under the curve (AUC), along with the calendar day, for the entire influenza season using trapezoidal rule. Participants could be followed for varying days in the influenza season, therefore the AUC will be time weighted to 168 days: Time weighted AUC=((raw AUC \[time in days\])/(number of days used for analysis)) \* 168

Time frame:
210 days (during the influenza season, starting on 01 May 2019 and ending on or before 15 October 2019)
Reported as:
Mean · weighted days
Severity of Influenza-like Illness (ILI) Derived From Daily ILI eDiary as Time Weighted AUC
weighted daysMVA-NP+M1 GroupSaline Placebo Group
Severity of Influenza-like Illness (ILI) Derived From Daily ILI eDiary as Time Weighted AUC5490 ± 23.49445297 ± 21.3996
Statistical analysis
  • MVA-NP+M1 Group vs Saline Placebo Group · ANOVA · p = 0.9550 · Geometric mean ratio (active vs placebo): 0.99 · 95% CI 0.83 to 1.19
  • MVA-NP+M1 Group vs Saline Placebo Group · ANOVA · p = 0.8933 · Geometric mean ratio (active vs placebo): 1 · 95% CI 1 to 1
  • MVA-NP+M1 Group vs Saline Placebo Group · ANOVA · p = 0.2156 · Geometric mean ratio (active vs placebo): 0.87 · 95% CI 0.7 to 1.09
  • MVA-NP+M1 Group vs Saline Placebo Group · ANOVA · p = 0.2216 · Geometric mean ratio (active vs placebo): 0.88 · 95% CI 0.71 to 1.10
  • MVA-NP+M1 Group vs Saline Placebo Group · ANOVA · p = 0.2306 · Geometric mean ratio (active vs placebo): 0.87 · 95% CI 0.69 to 1.09
  • MVA-NP+M1 Group vs Saline Placebo Group · ANOVA · p = 0.8038 · Geometric mean ratio (active vs placebo): 0.99 · 95% CI 0.97 to 1.13
  • MVA-NP+M1 Group vs Saline Placebo Group · ANOVA · p = 0.9319 · Geometric mean ratio (active vs placebo): 1.01 · 95% CI 0.84 to 1.21
  • MVA-NP+M1 Group vs Saline Placebo Group · ANOVA · p = 0.8399 · Geometric mean ratio (active vs placebo): 1.01 · 95% CI 0.86 to 1.19
SecondaryNumber of Participants With Immunogenic Response to MVA-NP+M1 (as Assessed Via the Frequency of Influenza-specific T-cells)

The numbers of immunogenic Participants (with positive immune response as assessed at Day 28 and week 26 in relation to the baseline day 0 Immunogenicity) were listed. The immunogenicity here was determined via the frequency of influenza-specific T-cells measured by IFN-γ/granzyme B ELISpot assay (enzyme linked immunospot) where the adjusted Spot Forming Units (SFU) per million PBMCs (peripheral blood mononuclear cells) after background subtraction (dimethyl sulfoxide, DMSO) were counted. The immunogenicity analyses were conducted only in the Immunology Analysis Set of Participants.

Time frame:
Day 28 and Week 26
Reported as:
Count of participants · Participants
Number of Participants With Immunogenic Response to MVA-NP+M1 (as Assessed Via the Frequency of Influenza-specific T-cells)
ParticipantsMVA-NP+M1 GroupSaline Placebo Group
Participants with immunogenic response (as the frequency of influenza-specific T-cells) at Day 282021
Participants with Immunogenic response (via the frequency of influenza-specific T-cells) at Week 261613
Statistical analysis
  • MVA-NP+M1 Group vs Saline Placebo Group · ANCOVA · p = 0 · Least squares mean difference: 743.78 · 95% CI 443.71 to 1043.84
  • MVA-NP+M1 Group vs Saline Placebo Group · ANCOVA · p = 0.0673 · Least squares mean difference: 177.10 · 95% CI -13.14 to 367.33

Adverse events

Collected over Unsolicited non-serious adverse events will be collected for 28 days post-vaccination. Hospitalisations, other serious adverse events and or adverse events of special interest will be collected for the duration of the influenza season. Solicited adverse events, including solicited local injection site reactions (ISR) and solicited systemic reactions, will be collected for 7 days post-vaccination. These will be recorded daily in the eDiary for all participants.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MVA-NP+M1 Group0/1,077 (0%)18/1,077 (1.7%)524/1,077 (48.7%)
Saline Placebo Group1/1,075 (0.1%)22/1,075 (2%)435/1,075 (40.5%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventMVA-NP+M1 GroupSaline Placebo Group
PneumoniaInfections and infestations2/10773/1075
AsthmaRespiratory, thoracic and mediastinal disorders0/10772/1075
DiverticulitisInfections and infestations1/10771/1075
AppendicitisInfections and infestations0/10771/1075
Infective exacerbation of chronic obstructive airways diseaseInfections and infestations0/10771/1075
Pneumonia mycoplasmalInfections and infestations0/10771/1075
Pyelonephritis acuteInfections and infestations0/10771/1075
TonsillitisInfections and infestations0/10771/1075
COPDRespiratory, thoracic and mediastinal disorders1/10771/1075
Bronchial hyperreactivityRespiratory, thoracic and mediastinal disorders0/10771/1075
Most frequent other events
Showing 10 of 29
Most frequent other events
EventMVA-NP+M1 GroupSaline Placebo Group
HeadacheNervous system disorders145/1077122/1075
Oropharyngeal painRespiratory, thoracic and mediastinal disorders115/1077119/1075
RhinorrhoeaRespiratory, thoracic and mediastinal disorders89/107793/1075
Nasal congestionRespiratory, thoracic and mediastinal disorders90/107784/1075
CoughRespiratory, thoracic and mediastinal disorders73/107786/1075
Injection site painGeneral disorders73/10770/1075
MyalgiaMusculoskeletal and connective tissue disorders59/107736/1075
FatigueGeneral disorders43/107724/1075
Upper respiratory tract infectionInfections and infestations20/107731/1075
PyrexiaGeneral disorders30/10770/1075

Baseline characteristics

Age, Continuous
Age, Continuous(years)MVA-NP+M1 GroupSaline Placebo GroupTotal
Mean43.6 ± 18.9343.8 ± 18.4043.7 ± 18.66
Sex/Gender, Customized
Sex/Gender, Customized(Participants)MVA-NP+M1 GroupSaline Placebo GroupTotal
Female6316311262
Male445443888
Unknown112
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MVA-NP+M1 GroupSaline Placebo GroupTotal
Hispanic or Latino101121
Not Hispanic or Latino106110522113
Unknown or Not Reported61218
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MVA-NP+M1 GroupSaline Placebo GroupTotal
American Indian or Alaska Native101
Asian143118261
Native Hawaiian or Other Pacific Islander81321
Black or African American9716
White8828921774
More than one race538
Unknown or Not Reported294271
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)MVA-NP+M1 GroupSaline Placebo GroupTotal
Mean28.36 ± 6.72728.26 ± 6.14328.31 ± 6.435
Body Temperature
Body Temperature(degree Celsius)MVA-NP+M1 GroupSaline Placebo GroupTotal
Mean36.44 ± 0.42036.44 ± 0.40136.44 ± 0.410
08

Study locations

9 sites
  • Paratus Clinical Pty Ltd
    Blacktown, New South Wales 2148, Australia
  • Genesis Research Services
    Broadmeadow, New South Wales 2292, Australia
  • Paratus Clinical Pty Ltd
    Kanwal, New South Wales 2259, Australia
  • Scientia Clinical Research
    Sydney, New South Wales 2031, Australia
  • University of Sunshine Coast (USC)
    Morayfield, Queensland 4506, Australia
  • University of Sunshine Coast (USC)
    Sippy Downs, Queensland 4556, Australia
  • Mater Research
    South Brisbane, Queensland 4101, Australia
  • CMAX
    Adelaide, South Australia 5000, Australia
  • Nucleus Network Pty Ltd
    Melbourne, Victoria 3004, Australia
09

References and documents

Publications

  • Evans TG, Bussey L, Eagling-Vose E, Rutkowski K, Ellis C, Argent C, Griffin P, Kim J, Thackwray S, Shakib S, Doughty J, Gillies J, Wu J, Druce J, Pryor M, Gilbert S. Efficacy and safety of a universal influenza A vaccine (MVA-NP+M1) in adults when given after seasonal quadrivalent influenza vaccine immunisation (FLU009): a phase 2b, randomised, double-blind trial. Lancet Infect Dis. 2022 Jun;22(6):857-866. doi: 10.1016/S1473-3099(21)00702-7. Epub 2022 Mar 16. PubMed 35305317 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Oct 2019, 6 months.

Results were first posted in Apr 2021, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2019
First posted
Mar 19, 2019
StartActual
Mar 18, 2019
Primary completionActual
Oct 15, 2019
CompletionActual
Jan 21, 2020
Results first posted
Apr 26, 2021
Last update
Apr 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03880474
Lead sponsor
Barinthus Biotherapeutics
Collaborators
Clinical Network Services (CNS) Pty Ltd
Responsible party
Sponsor
First posted
Mar 19, 2019
Start date
Mar 18, 2019
Primary completion
Oct 15, 2019
Completion
Jan 21, 2020
Results posted
Apr 26, 2021
Last update
Apr 26, 2021

Study contacts

James Vandeleur, MD
principal investigator · Paratus Clinical Pty Ltd

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MVA-NP+M1

Start the discussion